Ahmad Fahmy, OD
Corneal and Contact Management · Minneapolis, MNNPI 1598750929
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.8%. 2025 is the largest year on record at $69,308, 2.7 times the $25,712 reported in 2019. Among corneal and contact management clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $699.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- Sun Pharmaceutical Industries Inc.$42K
- Sight Sciences, Inc.$28K
- Tarsus Pharmaceuticals, Inc.$27K
- Oyster Point Pharma, Inc.$22K
- Dompe US, Inc.$16K
- plus $38K from 10 others
Across 12 payments — averaging $5163.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$43K
- Shire North American Group Inc$18K
- Takeda Pharmaceuticals U.S.A., Inc.$434
What the payments were for
- Consulting fees$62,99828%
- Speaking & faculty fees$128,05658%
- Travel & lodging$24,66711%
- Food & beverage$6,0653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $48,257 |
| Sun Pharmaceutical Industries Inc. | 45 | $41,565 |
| Sight Sciences, Inc. | 44 | $27,946 |
| Tarsus Pharmaceuticals, Inc. | 31 | $27,483 |
| Oyster Point Pharma, Inc. | 36 | $21,947 |
| Dompe US, Inc. | 23 | $16,105 |
| Biotissue Holdings Inc. | 30 | $14,692 |
| Alcon | 14 | $10,725 |
| Bausch & Lomb Americas Inc. | 9 | $5,451 |
| Alcon Research LLC | 5 | $3,150 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $1,750 |
| Kala Pharmaceuticals, Inc. | 2 | $1,054 |
| Amgen | 4 | $1,025 |
| Ocular Therapeutix, Inc. | 4 | $412 |
| Novartis | 4 | $209 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$41,039
- XDEMVY$24,608
- VUITY$23,352
- TYRVAYA$21,512
- TearCare SmartLid$12,784
- TEARCARE(TM) (2.2) SYSTEM KIT$12,784
- TearCare$11,214
- RESTASIS MULTIDOSE$7,813
- TRYPTYR$5,933
- RESTASIS$5,599
- XIIDRA$5,454
- MIEBO$5,305
- Prokera$5,221
- LUMIGAN$5,179
- TEARCARE SYSTEM$3,450
- COMBIGAN$3,179
- AmnioGraft$3,019
- AmnioGuard$2,675
- ALPHAGAN P$2,000
- Tecnis Symfony IOL$1,750
How this compares
$221,786 in reported general payments places this provider in the 95th percentile of 30 corneal and contact management providers in Minnesota.
See all corneal and contact management providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 16 | $450,406 |
| RestasisCyclosporine | 211 | $260,508 |
| XdemvyLotilaner | 52 | $97,999 |
| TyrvayaVarenicline Tartrate | 115 | $83,534 |
| MieboPerfluorohexyloctane/Pf | 108 | $82,677 |
| XiidraLifitegrast | 49 | $72,232 |
| Cyclosporine | 58 | $39,085 |
| CequaCyclosporine | 29 | $38,466 |
| VevyeCyclosporine | 40 | $31,914 |
| VyzultaLatanoprostene Bunod | 21 | $15,443 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $12,847 |
| LumiganBimatoprost | 17 | $10,954 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $7,811 |
| Fluorometholone | 84 | $6,622 |
| Prednisolone Acetate | 98 | $4,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $16,105 | $450,40616 claims |
| AbbVieRestasis, Combigan, Lumigan | $48,257 | $284,309252 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $5,451 | $170,352178 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $27,483 | $97,99952 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $21,947 | $83,534115 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $41,565 | $38,46629 claims |
| AlconSimbrinza | $10,725 | $4,20021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 corneal and contact management providers in Minnesota.
Other corneal and contact management in Minneapolis
- Cheryl Zabrowski FlogelMinneapolis$228
- Neelu HiraMinneapolis$24
- Scott HauswirthBloomington$73K
- Mark BuboltzBloomington$6K
- Tina McCartyFridley$3K
- Thomas EltonEdina$2K
- Alicia AlvaradoFridley$2K
- Johnna HobbsBloomington$2K
- Michael NovakWillmar$2K
- Robert DingaOakdale$962
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.